Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nafamostat - Ensysce Biosciences

Next Previous
Drug Profile

Nafamostat - Ensysce Biosciences

Alternative Names: Nafamostat mesilate - Ensysce Biosciences; Nafamostat mesylate - Ensysce Biosciences; Repurposed nafamostat mesilate - Ensysce Biosciences

Latest Information Update: 02 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ensysce Biosciences
  • Class Anti-inflammatories; Anticoagulants; Antivirals; Guanidines; Mucolytics; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections
  • No development reported Middle East respiratory syndrome coronavirus

Most Recent Events

  • 29 Aug 2024 Ensysce BioSciences plans a clinical trial for COVID 2019 infectins (Combination Therapy) (Ensysce BioSciences pipeline, August 2024)
  • 29 Jul 2024 Nafamostat is still in phase I trials for COVID-19-infections (In volunteers) in USA (PO, Liquid) (Ensysce Biosciences pipeline, July 2024)
  • 28 May 2024 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus in USA (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top